Adolescent and young adult oncology clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 9, 2012, Pages 1112-1150

  Coccia, Peter F ^a   Altman, Jessica ^b   Bhatia, Smita ^c   Borinstein, Scott C ^d   Flynn, Joseph ^e   George, Suzanne ^f   Goldsby, Robert ^g   Hayashi, Robert ^h   Huang, Mary S ⁱ   Johnson, Rebecca H ^j   Beaupin, Lynda Kwon ^k   Link, Michael P ^l   Oeffinger, Kevin C ^m   Orr, Kathleen M ⁿ   Pappo, Alberto S ^o   Reed, Damon ^p   Spraker, Holly L ^q   Thomas, Deborah A ^r   Von Mehren, Margaret ^s   Wechsler, Daniel S ^t   Whelan, Kimberly F ^u   Zebrack, Brad ^v   Sundar, Hema ^w   Shead, Dorothy A ^w   more..

^a NEBRASKA MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Dana Farber Brigham and Women's Cancer Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BARNES JEWISH HOSPITAL   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l STANFORD CANCER INSTITUTE   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q UNIVERSITY OF UTAH   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t DUKE CANCER INSTITUTE   (United States)

^u UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^v UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^w NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BUSULFAN; CARBON MONOXIDE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GONADORELIN AGONIST; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; MEDROXYPROGESTERONE; METHOTREXATE; MISMATCH REPAIR PROTEIN PMS2; PREDNISONE; PROCARBAZINE; PROTEIN MLH1; PROTEIN MSH6; SUCCINATE DEHYDROGENASE; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADENOMATOUS POLYP; ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; ALTERNATIVE MEDICINE; ANTICIPATORY NAUSEA AND VOMITING; ASYMPTOMATIC DISEASE; BEHAVIOR; BLADDER DISEASE; BLOOD PRESSURE MEASUREMENT; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER INCIDENCE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD CANCER; CHROMOSOMAL INSTABILITY; CHRONIC COUGH; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; COWDEN SYNDROME; CRYOPRESERVATION; DYSPNEA; EMOTIONALITY; ENVIRONMENTAL EXPOSURE; EWING SARCOMA; FAMILIAL CANCER; FAMILY HISTORY; FAMILY RELATION; FEMALE INFERTILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GERM CELL TUMOR; GONAD DYSFUNCTION; GONAD FUNCTION; GONADOTROPIN DEFICIENCY; GRAFT VERSUS HOST REACTION; GROWTH HORMONE DEFICIENCY; HAIR LOSS; HAND PARESTHESIA; HEALTH CARE PERSONNEL; HEARING IMPAIRMENT; HEARING TEST; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; HUMAN RELATION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTHYROIDISM; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTERPERSONAL COMMUNICATION; KIDNEY DISEASE; KIDNEY FAILURE; LEUKEMIA; LIFESTYLE MODIFICATION; LUNG TOXICITY; LYMPHOMA; MALE INFERTILITY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MANTLE FIELD RADIOTHERAPY; MEDICAID; MELANOMA; MENORRHAGIA; METASTASIS; MISMATCH REPAIR; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEPHROTOXICITY; NEUROPSYCHOLOGICAL TEST; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; ONCOLOGY; OVARIAN RESERVE; OVARIOPEXY; PARAGANGLIOMA; PARESTHESIA; PATIENT COMPLIANCE; PEER GROUP; PERICARDIAL DISEASE; PHEOCHROMOCYTOMA; PHYSICAL ACTIVITY; PNEUMONIA; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PSYCHOSOCIAL CARE; RADIATION DOSE; RAYNAUD PHENOMENON; REPRODUCTIVE PROCEDURE; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SOCIOECONOMICS; TERMINAL CARE; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; TINNITUS; TUMOR SUPPRESSOR GENE; URINALYSIS; UTERINE CERVIX CARCINOMA; UTERUS DISEASE; VAGINA CARCINOMA; VALVULAR HEART DISEASE; WHOLE BODY RADIATION;

EID: 84866549860     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0117     Document Type: Review

References (180)

1. Bleyer A, O'Leary M, Barr R, Ries L, eds. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.
2. Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 2007;110:2385-2393.
3. Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer 2008;50:1101-1104.
4. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006;107:1645-1655.
5. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin 2007;57:242-255.
6. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-298.
7. Ramphal R, Meyer R, Schacter B, et al. Active therapy and models of care for adolescents and young adults with cancer. Cancer 2011;117:2316-2322.
8. Closing the gap: research and care imperatives for adolescents and young adults with cancer: report of the adolescent and young adult oncology progress review group. Available at: http://planning.cancer.gov/library/AYAO-PRG-Report- 2006-FINAL.pdf. Accessed July 25, 2012.
9. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist 2006;11:590-601.
10. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
11. Zebrack B, Mathews-Bradshaw B, Siegel S. Quality cancer care for adolescents and young adults: a position statement. J Clin Oncol 2010;28:4862-4867.
12. Alman BA, Pajerski ME, Diaz-Cano S, et al. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol 1997;6:98-101.
13. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiationinduced? Ophthalmology 1984;91:1351-1355.
14. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
15. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712-1721.
16. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314-318.
17. Friedman JM. Neurofibromatosis 1. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle, WA: University of Washington; 1993-1998. Initial Posting: October 2, 1998; Last Update: June 2, 2009.
18. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:99-119.
19. Bryant H. Screening for cancer in children, adolescents, and young adults: questions and more questions. Cancer 2011;117:2275-2280.
20. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr 1991;119:725-732.
21. Klein-Geltink J, Pogany L, Mery LS, et al. Impact of age and diagnosis on waiting times between important healthcare events among children 0 to 19 years cared for in pediatric units: the Canadian Childhood Cancer Surveillance and Control Program. J Pediatr Hematol Oncol 2006;28:433-439.
22. Dang-Tan T, Trottier H, Mery LS, et al. Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer 2008;51:468-474.
23. Martin S, Ulrich C, Munsell M, et al. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 2007;12:816-824.
24. Ferrari A, Thomas D, Franklin AR, et al. Starting an adolescent and young adult program: some success stories and some obstacles to overcome. J Clin Oncol 2010;28:4850-4857.
25. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780.
26. de Bont JM, Holt Bvd, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18:2032-2035.
27. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standardrisk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008;26:1843-1849.
28. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646-1654.
29. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918.
30. Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 2003;98:571-580.
31. Scurr M, Judson I. How to treat the Ewing's family of sarcomas in adult patients. Oncologist 2006;11:65-72.
32. Sandlund JT. Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program 2007:297-303.
33. Tai E, Pollack LA, Townsend J, et al. Differences in non-Hodgkin lymphoma survival between young adults and children. Arch Pediatr Adolesc Med 2010;164:218-224.
34. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011;25:153-160.
35. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health 1997;21:366-373.
36. Shochat SJ, Fremgen AM, Murphy SB, et al. Childhood cancer: patterns of protocol participation in a national survey. CA Cancer J Clin 2001;51:119-130.
37. Downs-Canner S, Shaw PH. A comparison of clinical trial enrollment between adolescent and young adult (AYA) oncology patients treated at affiliated adult and pediatric oncology centers. J Pediatr Hematol Oncol 2009;31:927-929.
38. Parsons HM, Harlan LC, Seibel NL, et al. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol 2011;29:4045-4053.
39. Howell DL, Ward KC, Austin HD, et al. Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. J Clin Oncol 2007;25:4610-4615.
40. Albritton KH, Wiggins CH, Nelson HE, Weeks JC. Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol 2007;25:4616-4621.
41. Bleyer A. The Quid Pro Quo of pediatric versus adult services for older adolescent cancer patients. Pediatr Blood Cancer 2010;54:238-241.
42. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010;28:4790-4799.
43. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med 2004;2:61-70.
44. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing riskbased health care for survivors. CA Cancer J Clin 2004;54:208-236.
45. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010;174:840-850.
46. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831-4841.
47. Janson C, Leisenring W, Cox C, et al. Predictors of marriage and divorce in adult survivors of childhood cancers: a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2009;18:2626-2635.
48. Bleyer A, Choi M, Wang SJ, et al. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;53:1205-1210.
49. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 2009;115:23-35.
50. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-8596.
51. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-760.
52. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000;82:1636-1645.
53. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-1538.
54. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, et al. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007;5:44-50.
55. Armenian SH, Sun CL, Kawashima T, et al. Long-term healthrelated outcomes in survivors of childhood cancer treated with hematopoietic cell transplantation (HCT) versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011;118:1413-1420.
56. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175-1183.
57. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011;117:2301-2310.
58. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
59. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-218.
60. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 2009;5:88-99.
61. Redig AJ, Brannigan R, Stryker SJ, et al. Incorporating fertility preservation into the care of young oncology patients. Cancer 2011;117:4-10.
62. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2009;27:2677-2685.
63. Green DM, Nolan VG, Kawashima T, et al. Decreased fertility among female childhood cancer survivors who received 22-27 Gy hypothalamic/pituitary irradiation: a report from the Childhood Cancer Survivor Study. Fertil Steril 2011;95:1922-1927, 1927 e1921.
64. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006;91:1723-1728.
65. Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-2381.
66. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73:1304-1312.
67. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64-73.
68. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729.
69. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
70. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatmentrelated risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101-108.
71. Haukvik UKH, Dieset I, Bjoro T, et al. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006;17:1428-1433.
72. Terenziani M, Piva L, Meazza C, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril 2009;91:935, e915-936.
73. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropinreleasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-697.
74. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010;21:2052-2060.
75. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropinreleasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906-914, e901-904.
76. Azim H Jr, Gentilini O, Locatelli M, et al. Managing pregnant women with cancer: personal considerations and a review of the literature. Ecancermedicalscience 2011;5:204.
77. Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treat Rev 2010;36:110-121.
78. Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat Rev 2010;36:101-109.
79. Chemaitilly W, Sklar CA. Endocrine complications in longterm survivors of childhood cancers. Endocr Relat Cancer 2010;17:R141-159.
80. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001;91:613-621.
81. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
82. Zebrack BJ. Psychological, social, and behavioral issues for young adults with cancer. Cancer 2011;117:2289-2294.
83. Abrams AN, Hazen EP, Penson RT. Psychosocial issues in adolescents with cancer. Cancer Treat Rev 2007;33:622-630.
84. Zebrack B, Isaacson S. Psychosocial care of adolescent and young adult patients with cancer and survivors. J Clin Oncol 2012;30:1221-1226.
85. D'Agostino NM, Penney A, Zebrack B. Providing developmentally appropriate psychosocial care to adolescent and young adult cancer survivors. Cancer 2011;117:2329-2334.
86. Zeltzer LK. Cancer in adolescents and young adults psychosocial aspects. Long-term survivors. Cancer 1993;71:3463-3468.
87. Arnett JJ. Emerging adulthood. A theory of development from the late teens through the twenties. Am Psychol 2000;55:469-480.
88. Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock 'n' roll: caring for adolescents and young adults with cancer. J Clin Oncol 2010;28:4825-4830.
89. Vinokur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA. The process of recovery from breast cancer for younger and older patients. Changes during the first year. Cancer 1990;65:1242-1254.
90. Mor V, Allen S, Malin M. The psychosocial impact of cancer on older versus younger patients and their families. Cancer 1994;74:2118-2127.
91. Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. Cancer 2006;107:1752-1759.
92. Kazak AE, Derosa BW, Schwartz LA, et al. Psychological outcomes and health beliefs in adolescent and young adult survivors of childhood cancer and controls. J Clin Oncol 2010;28:2002-2007.
93. Krull KR, Huang S, Gurney JG, et al. Adolescent behavior and adult health status in childhood cancer survivors. J Cancer Surviv 2010;4:210-217.
94. Emmons K, Li FP, Whitton J, et al. Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 2002;20:1608-1616.
95. Lown EA, Goldsby R, Mertens AC, et al. Alcohol consumption patterns and risk factors among childhood cancer survivors compared to siblings and general population peers. Addiction 2008;103:1139-1148.
96. Cox CL, McLaughlin RA, Steen BD, Hudson MM. Predicting and modifying substance use in childhood cancer survivors: application of a conceptual model. Oncol Nurs Forum 2006;33:51-60.
97. Zebrack B, Bleyer A, Albritton K, et al. Assessing the health care needs of adolescent and young adult cancer patients and survivors. Cancer 2006;107:2915-2923.
98. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-1585.
99. Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol 2010;28:4800-4809.
100. Kondryn HJ, Edmondson CL, Hill J, Eden TO. Treatment nonadherence in teenage and young adult patients with cancer. Lancet Oncol 2011;12:100-108.
101. Windebank KP, Spinetta JJ. Do as I say or die: compliance in adolescents with cancer. Pediatr Blood Cancer 2008;50:1099-1100.
102. Kato PM, Cole SW, Bradlyn AS, Pollock BH. A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. Pediatrics 2008;122:e305-317.
103. Kahana S, Drotar D, Frazier T. Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol 2008;33:590-611.
104. Albritton K, Barr R, Bleyer A. The adolescence of young adult oncology. Semin Oncol 2009;36:478-488.
105. Kyngas H, Mikkonen R, Nousiainen EM, et al. Coping with the onset of cancer: coping strategies and resources of young people with cancer. Eur J Cancer Care (Engl) 2001;10:6-11.
106. Zebrack BJ, Oeffinger KC, Hou P, Kaplan S. Advocacy skills training for young adult cancer survivors: the Young Adult Survivors Conference at Camp Mak-a-Dream. Support Care Cancer 2006;14:779-782.
107. Treadgold CL, Kuperberg A. Been there, done that, wrote the blog: the choices and challenges of supporting adolescents and young adults with cancer. J Clin Oncol 2010;28:4842-4849.
108. Zebrack B. Information and service needs for young adult cancer patients. Support Care Cancer 2008;16:1353-1360.
109. Zebrack B. Information and service needs for young adult cancer survivors. Support Care Cancer 2009;17:349-357.
110. Palmer S, Mitchell A, Thompson K, Sexton M. Unmet needs among adolescent cancer patients: a pilot study. Palliat Support Care 2007;5:127-134.
111. Fallon S, Smith J, Morgan S, et al. 'Pizza, patients and points of view': involving young people in the design of a post registration module entitled the adolescent with cancer. Nurse Educ Pract 2008;8:140-147.
112. Rabin C, Simpson N, Morrow K, Pinto B. Behavioral and psychosocial program needs of young adult cancer survivors. Qual Health Res 2011;21:796-806.
113. Kirchhoff AC, Leisenring W, Krull KR, et al. Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. Med Care 2010;48:1015-1025.
114. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2396-2404.
115. Soliman H, Agresta SV. Current issues in adolescent and young adult cancer survivorship. Cancer Control 2008;15:55-62.
116. Oeffinger KC, Tonorezos ES. The cancer is over, now what?: Understanding risk, changing outcomes. Cancer 2011;117:2250-2257.
117. Woodward E, Jessop M, Glaser A, Stark D. Late effects in survivors of teenage and young adult cancer: does age matter? Ann Oncol 2011;22:2561-2568.
118. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582.
119. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328-2338.
120. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-3494.
121. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886.
122. Curtis RE, Freedman DM, Ron E, et al, eds. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.
123. Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008;14:429-434.
124. Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010;20:67-78.
125. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-1095.
126. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009;27:2356-2362.
127. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
128. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980.
129. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437.
130. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010;152:444-455; W144-454.
131. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
132. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096-4104.
133. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114-1130.
134. Gilligan T. Testicular cancer survivorship. Hematol Oncol Clin North Am 2011;25:627-639, x.
135. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-1066.
136. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.
137. Wierecky J, Kollmannsberger C, Boehlke I, et al. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol 2005;131:255-260.
138. Howard R, Gilbert E, Lynch CF, et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol 2008;18:416-421.
139. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of longterm risk. J Natl Cancer Inst 2007;99:1634-1643.
140. Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second nonhematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007;106:439-451.
141. Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850-1857.
142. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010;102:1272-1283.
143. Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer 2011;117:625-634.
144. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0; 2008.
145. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 2011;108:619-628.
146. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999;51:35-42.
147. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-214.
148. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-475.
149. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20- year follow-up study. J Clin Oncol 2010;28:4649-4657.
150. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 2011;60:516-526.
151. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
152. Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002;95:2431-2441.
153. Fossa SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99:533-544.
154. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91-96.
155. Haugnes HS, Aass N, Fossa SD, et al. Pulmonary function in longterm survivors of testicular cancer. J Clin Oncol 2009;27:2779-2786.
156. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 2009;27:2339-2355.
157. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003;21:3255-3261.
158. Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009;101:1682-1695.
159. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005;23:6508-6515.
160. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006;24:5277-5282.
161. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-937.
162. Chow EJ, Friedman DL, Stovall M, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2009;53:432-437.
163. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010;174:741-752.
164. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200-207.
165. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-396.
166. Liles A, Blatt J, Morris D, et al. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleve Clin J Med 2008;75:531-539.
167. Freyer DR. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol 2010;28:4810-4818.
168. Nathan PC, Hayes-Lattin B, Sisler JJ, Hudson MM. Critical issues in transition and survivorship for adolescents and young adults with cancers. Cancer 2011;117:2335-2341.
169. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol 2006;24:5117-5124.
170. Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol 2008;26:1073-1079.
171. Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009;27:1054-1061.
172. Blaauwbroek R, Tuinier W, Meyboom-de Jong B, et al. Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. Lancet Oncol 2008;9:232-238.
173. Wallace WH, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001;323:271-274.
174. Oeffinger KC. Longitudinal risk-based health care for adult survivors of childhood cancer. Curr Probl Cancer 2003;27:143-167.
175. Wein S, Pery S, Zer A. Role of palliative care in adolescent and young adult oncology. J Clin Oncol 2010;28:4819-4824.
176. Pritchard S, Cuvelier G, Harlos M, Barr R. Palliative care in adolescents and young adults with cancer. Cancer 2011;117:2323-2328.
177. Lyon ME, McCabe MA, Patel KM, D'Angelo LJ. What do adolescents want? An exploratory study regarding end-of-life decision-making. J Adolesc Health 2004;35:529, e521-526.
178. Webb NM, Tucker D. Young adults' opinions about hospice and home death. J Palliat Med 2009;12:337-342.
179. Bell CJ, Skiles J, Pradhan K, Champion VL. End-of-life experiences in adolescents dying with cancer. Support Care Cancer 2010;18:827-835.
180. Wiener L, Ballard E, Brennan T, et al. How I wish to be remembered: the use of an advance care planning document in adolescent and young adult populations. J Palliat Med 2008;11:1309-1313.